| 1.69 -0.115 (-6.37%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.16 | 1-year : | 2.52 |
| Resists | First : | 1.85 | Second : | 2.16 |
| Pivot price | 1.63  |
|||
| Supports | First : | 1.62 | Second : | 1.49 |
| MAs | MA(5) : | 1.69 |
MA(20) : | 1.65 |
| MA(100) : | 1.96 |
MA(250) : | 3.97 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70.5 |
D(3) : | 60.2 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 9.72 | Low : | 1.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PMVP ] has closed below upper band by 32.8%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.8 - 1.81 | 1.81 - 1.82 |
| Low: | 1.67 - 1.68 | 1.68 - 1.69 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Sat, 20 Apr 2024
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth - Simply Wall St
Sat, 13 Apr 2024
PMVP Stock Price and Chart — NASDAQ:PMVP — TradingView - TradingView
Fri, 12 Apr 2024
PMV Pharmaceuticals (NASDAQ:PMVP) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Mon, 18 Mar 2024
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late ... - GlobeNewswire
Thu, 29 Feb 2024
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights - GlobeNewswire
Mon, 26 Feb 2024
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 99.4 (%) |
| Shares Short | 2,600 (K) |
| Shares Short P.Month | 1,980 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -29.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -1.18 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|